{
  "id": 20714326,
  "title": "Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.",
  "url": "https://urgent.news/2026/11/19/modernas-cancer-vaccine-worked-and-the-stock-plunged-anyway-heres-20714326",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T06:20:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/modernas-cancer-vaccine-worked-and-stock-plunged-anyway-heres-what-investors-are-missing"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsModerna’s personalized melanoma vaccine, paired with Merck’s Keytruda, cut the risk of recurrence or death by 42% in a Phase 3 trial.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.",
        "url": "https://urgent.news/2026/11/19/modernas-cancer-vaccine-worked-and-the-stock-plunged-anyway-heres",
        "published": "2026-11-19T06:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}